6-K 1 a1754n.htm DIRECTOR/PDMR SHAREHOLDING a1754n
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of June 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
☒
 
Form 40-F
☐
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
      99.1
17 June 2025 - “Director/PDMR Shareholding”
 
 
99.1
 
 
​Haleon plc: Director/PDMR Shareholding
​ 
​17 June 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of a Transaction by a Person Discharging Managerial Responsibilities ("PDMR").
 
On 13 June 2025, the Company was notified of the following transaction as detailed below.
 
1  
 
Details of the person discharging managerial responsibilities / person closely associated  
 
a)  
 
Name  
 
Marie-Anne Aymerich
2  
 
Reason for the notification  
 
a)  
 
Position/status  
 
Independent Non-Executive Director - PDMR
b)  
 
Initial notification /Amendment  
 
Initial Notification 
3  
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
 
a)  
 
Name  
 
Haleon plc 
b)  
 
LEI  
 
549300PSB3WWEODCUP19 
4  
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
 
a)  
 
Description of the financial instrument, type of instrument  
 
Identification code  
 
Ordinary Shares of £0.01 each
 
GB00BMX86B70   
 
b)  
 
Nature of the transaction  
 
Acquisition of Ordinary Shares as a result of dividend reinvestment
 
c)  
 
Price(s) and volume(s)  
 
 
 
 
 
 
Price(s) 
Volume(s) 
 
 
 
£4.07
320
 
 
 
 
 
 
d)  
 
Aggregated information  
 N/A
 
 
- Aggregated volume 
 
 
 
- Price 
 
 
 
e)  
 
Date of the transaction  
 
12 June 2025
 
f)  
 
Place of the transaction  
 
London Stock Exchange (XLON) 
 
Amanda Mellor
Company Secretary
 
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com. 

 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: June 17, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary